MX2022006274A - Metodos de tratamiento de la infeccion por vih-1. - Google Patents

Metodos de tratamiento de la infeccion por vih-1.

Info

Publication number
MX2022006274A
MX2022006274A MX2022006274A MX2022006274A MX2022006274A MX 2022006274 A MX2022006274 A MX 2022006274A MX 2022006274 A MX2022006274 A MX 2022006274A MX 2022006274 A MX2022006274 A MX 2022006274A MX 2022006274 A MX2022006274 A MX 2022006274A
Authority
MX
Mexico
Prior art keywords
infection
hiv
agents
combination
methods
Prior art date
Application number
MX2022006274A
Other languages
English (en)
Inventor
Carolyn Luscombe
Gary Ewart
Michelle Miller
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904453A external-priority patent/AU2019904453A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of MX2022006274A publication Critical patent/MX2022006274A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La terapia antirretroviral actual (ART) es una combinación de 2-3 agentes antirretrovirales que ha tenido éxito en la reducción del ARN del VIH-1 en la sangre y ha mejorado la morbilidad y mortalidad de la infección por VIH-1 y Sida. A pesar del potente ATR, la erradicación de la infección por VIH-1 sigue siendo difícil de lograr y existe la posibilidad de que el virus se reproduzca persistentemente en los reservorios virales que pueden seguir impulsando la progresión de la enfermedad patógena. Por consiguiente, existe la necesidad de agentes que ayuden a erradicar la infección por VIH-1. La presente invención se refiere al tratamiento de la infección por VIH-1 mediante la administración de N-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno -2-carboxamida en combinación con agentes antirretrovirales.
MX2022006274A 2019-11-26 2020-11-25 Metodos de tratamiento de la infeccion por vih-1. MX2022006274A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904453A AU2019904453A0 (en) 2019-11-26 Methods of treating HIV-1 infection
AU2020902273A AU2020902273A0 (en) 2020-07-03 Methods of treating hiv-1 infection
PCT/AU2020/051273 WO2021102508A1 (en) 2019-11-26 2020-11-25 Methods of treating hiv-1 infection

Publications (1)

Publication Number Publication Date
MX2022006274A true MX2022006274A (es) 2022-10-13

Family

ID=76128599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006274A MX2022006274A (es) 2019-11-26 2020-11-25 Metodos de tratamiento de la infeccion por vih-1.

Country Status (12)

Country Link
US (1) US20220409587A1 (es)
EP (1) EP4065106A4 (es)
JP (1) JP2023503903A (es)
KR (1) KR20220104773A (es)
CN (1) CN114980885A (es)
AU (1) AU2020390851A1 (es)
BR (1) BR112022010161A2 (es)
CA (1) CA3158591A1 (es)
IL (1) IL293160A (es)
MX (1) MX2022006274A (es)
WO (1) WO2021102508A1 (es)
ZA (1) ZA202206123B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092180A1 (en) * 2021-11-24 2023-06-01 Biotron Limited Methods of treating sars-cov-2 infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1902017T3 (da) * 2005-06-24 2014-06-30 Biotron Ltd Antivirale acylguanidinforbindelser
WO2008096369A2 (en) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection

Also Published As

Publication number Publication date
BR112022010161A2 (pt) 2022-08-09
CA3158591A1 (en) 2021-06-03
AU2020390851A1 (en) 2022-06-09
ZA202206123B (en) 2023-11-29
JP2023503903A (ja) 2023-02-01
CN114980885A (zh) 2022-08-30
WO2021102508A1 (en) 2021-06-03
KR20220104773A (ko) 2022-07-26
EP4065106A1 (en) 2022-10-05
IL293160A (en) 2022-07-01
EP4065106A4 (en) 2023-12-20
US20220409587A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
Memariani et al. Melittin: a venom-derived peptide with promising anti-viral properties
CL2022002030A1 (es) Sars-cov-2 desoptimizados y métodos y usos de los mismos
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
ZA202206123B (en) Methods of treating hiv-1 infection
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201891941A1 (ru) Профилактическая лечебная композиция на основе пероксометаллата, в частности фармацевтическая композиция
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
ZA202209180B (en) Compositions and methods for treating long covid
CO2022015272A2 (es) Medicamento/agente para el tratamiento de coronavirus, infecciones retrovirales y hepatitis c
CO2022017989A2 (es) Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
WO2007098247A3 (en) Substituted taraxastanes useful for treating viral infections
CO2022015018A2 (es) Métodos y medios para modificar la hemodinámica en infecciones
WO2001089509A3 (en) Method of treating hiv-1 disease
MX2022013814A (es) Tratamiento de infecciones virales.
ZA200708539B (en) Methods of applying ionization radiation for therapy of HIV infection
AR125119A1 (es) Actividad antiviral de inhibidores de vps34
EA202191711A1 (ru) Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
AR125121A1 (es) Actividad antiviral de inhibidores de vps34
Pinnetti et al. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r‐based antiretroviral regimen in persons with suppressed HIV replication
ES2133408T3 (es) Nuevos aislados de virus vih-1 de un subtipo, y su diagnostico diferencial, vacuna contra la infeccion por vih-1 de este subtipo y procedimiento para preparar y usar el aislado de vih-1.
WO2021081515A3 (en) Compositions and methods for the treatment of human immunodeficiency virus
MX2021014247A (es) Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih).